# 177Lu-JH04 in Patients with FAP-Positive Tumors

> **NCT06636617** · EARLY_PHASE1 · RECRUITING · sponsor: **First Affiliated Hospital of Fujian Medical University** · enrollment: 9 (estimated)

## Conditions studied

- Patients with Advanced Metastatic FAP-Positive Tumors

## Interventions

- **DRUG:** 3.70 GBq (100 mCi) of 177Lu-JH04
- **DRUG:** 5.55 GBq (150 mCi) of 177Lu-JH04
- **DRUG:** 7.40 GBq (200 mCi) of 177Lu-JH04

## Key facts

- **NCT ID:** NCT06636617
- **Lead sponsor:** First Affiliated Hospital of Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-21
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06636617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06636617, "177Lu-JH04 in Patients with FAP-Positive Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06636617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*